Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M
“We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF and APONVIE,” said Craig Collard, CEO. “In addition to our revenue growth, we are extremely pleased with the continued progress made across all aspects of our business throughout the past year.” Preliminary Q4 … Read more